Apoptosis signaling proteins as prognostic biomarkers in colorectal cancer: A review

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1795, Issue 2, 2009, Pages 117-129

  Hector, Suzanne ^a   Prehn, Jochen H M ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

Apoptosis; Biomarker; Colorectal cancer; Prognosis

Indexed keywords

ALLOGRAFT INFLAMMATORY FACTOR 1; BH3 PROTEIN; BIOLOGICAL MARKER; CASPASE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PROTEIN BAX; PROTEIN BCL 2;

AUTOPHAGY; COLORECTAL CANCER; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; AUTOPHAGY; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CASPASES; COLORECTAL NEOPLASMS; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR MARKERS, BIOLOGICAL;

EID: 62849099895     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2008.12.002     Document Type: Review

References (182)

1. Goldberg R.M., Sargent D.J., Morton R.F., Fuchs C.S., Ramanathan R.K., Williamson S.K., Findlay B.P., Pitot H.C., and Alberts S.R. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 22 (2004) 23-30
2. Andre T., Boni C., Mounedji-Boudiaf L., Navarro M., Tabernero J., Hickish T., Topham C., Zaninelli M., Clingan P., Bridgewater J., Tabah-Fisch I., and de Gramont A. I. The multicenter international study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer, oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 350 (2004) 2343-2351
3. Saltz L.B., Cox J.V., Blanke C., Rosen L.S., Fehrenbacher L., Moore M.J., Maroun J.A., Ackland S.P., Locker P.K., Pirotta N., Elfring G.L., Miller L.L., and The Irinotecan Study G. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 343 (2000) 905-914
4. Benson III A.B., Schrag D., Somerfield M.R., Cohen A.M., Figueredo A.T., Flynn P.J., Krzyzanowska M.K., Maroun J., McAllister P., Van Cutsem E., Brouwers M., Charette M., and Haller D.G. American Society of Clinical Oncology Recommendations on adjuvant chemotherapy for stage ii colon cancer. J. Clin. Oncol. 22 (2004) 3408-3419
5. Jover R., Zapater P., Castells A., Llor X., Andreu M., Cubiella J., Pinol V., Xicola R.M., Bujanda L., Rene J.M., Clofent J., Bessa X., Morillas J.D., Nicolas-Perez D., Paya A., Alenda C., A., and for the Gastrointestinal Oncology Group of the Spanish Gastroenterological. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 55 (2006) 848-855
6. Carethers J.M., Smith E.J., Behling C.A., Nguyen L., Tajima A., Doctolero R.T., Cabrera B.L., Goel A., Arnold C.A., Miyai K., and Boland C.R. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 126 (2004) 394-401
7. Sinicrope F.A., Rego R.L., Halling K.C., Foster N., Sargent D.J., La Plant B., French A.J., Laurie J.A., Goldberg R.M., Thibodeau S.N., and Witzig T.E. Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology 131 (2006) 729-737
8. Gryfe R., Kim H., Hsieh E.T.K., Aronson M.D., Holowaty E.J., Bull S.B., Redston M., and Gallinger S. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N. Engl. J. Med. 342 (2000) 69-77
9. Sjo O.H., Lunde O.C., Nygaard K., Sandvik L., and Nesbakken A. Tumour location is a prognostic factor for survival in colonic cancer patients. Colorectal Dis. 10 (2008) 33-40
10. Petersen V.C., Baxter K.J., Love S.B., and Shepherd N.A. Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut 51 (2002) 65-69
11. Morris E., Maughan N.J., Forman D., and Quirke P. Who to treat with adjuvant therapy in Dukes B/Stage II colorectal cancer? - The need for high quality pathology. Gut (2007)
12. Johnston P.G., Lenz H.J., Leichman C.G., Danenberg K.D., Allegra C.J., Danenberg P.V., and Leichman L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 55 (1995) 1407-1412
13. Shirota Y., Stoehlmacher J., Brabender J., Xiong Y.P., Uetake H., Danenberg K.D., Groshen S., Tsao-Wei D.D., Danenberg P.V., and Lenz H.J. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol. 19 (2001) 4298-4304
14. Metzger R., Danenberg K., Leichman C.G., Salonga D., Schwartz E.L., Wadler S., Lenz H.J., Groshen S., Leichman L., and Danenberg P.V. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin. Cancer Res. 4 (1998) 2371-2376
15. van Triest B., Pinedo H.M., Blaauwgeers J.L.G., van Diest P.J., Schoenmakers P.S., Voorn D.A., Smid K., Hoekman K., Hoitsma H.F.W., and Peters G.J. Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin. Cancer Res. 6 (2000) 1063-1072
16. Tsuji T., Sawai T., Takeshita H., Nakagoe T., Hidaka S., Yamaguchi H., Yasutake T., Nagayasu T., and Tagawa Y. Tumor dihydropyrimidine dehydrogenase expression is a useful marker in adjuvant therapy with oral fluoropyrimidines after curative resection of colorectal cancer. Cancer Chemother. Pharmacol. 54 (2004) 531-536
17. Boyer J., Allen W.L., McLean E.G., Wilson P.M., McCulla A., Moore S., Longley D.B., Caldas C., and Johnston P.G. Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res. 66 (2006) 2765-2777
18. Hector S., Porter C.W., Kramer D.L., Clark K., Prey J., Kisiel N., Diegelman P., Chen Y., and Pendyala L. Polyamine catabolism in platinum drug action: interactions between oxaliplatin and the polyamine analogue N1,N11-diethylnorspermine at the level of spermidine/spermine N1-acetyltransferase. Mol. Cancer Ther. 3 (2004) 813-822
19. Varma R.R., Hector S.M., Clark K., Greco W.R., Hawthorn L., and Pendyala L. Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10. Oncol. Rep. 14 (2005) 925-932
20. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., Boldrick J.C., Sabet H., Tran T., Yu X., Powell J.I., Yang L., Marti G.E., Moore T., Hudson Jr. J., Lu L., Lewis D.B., Tibshirani R., Sherlock G., Chan W.C., Greiner T.C., Weisenburger D.D., Armitage J.O., Warnke R., Levy R., Wilson W., Grever M.R., Byrd J.C., Botstein D., Brown P.O., and Staudt L.M. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 (2000) 503-511
21. Fan C., Oh D.S., Wessels L., Weigelt B., Nuyten D.S., Nobel A.B., van't Veer L.J., and Perou C.M. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 355 (2006) 560-569
22. Igney F.H., and Krammer P.H. Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer 2 (2002) 277-288
23. Hockenbery D., Nunez G., Milliman C., Schreiber R.D., and Korsmeyer S.J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348 (1990) 334-336
24. Vaux D.L., Cory S., and Adams J.M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335 (1988) 440-442
25. Boise L.H., González-García M., Postema C.E., Ding L., Lindsten T., Turka L.A., Mao X., Nuñez G., and Thompson C.B. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74 (1993) 597-608
26. Kozopas K.M., Yang T., Buchan H.L., Zhou P., and Craig R.W. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc. Natl. Acad. Sci. U S A 90 (1993) 3516-3520
27. Zhou P., Qian L., Kozopas K.M., and Craig R.W. Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood 89 (1997) 630-643
28. Gibson L., Holmgreen S.P., Huang D.C., Bernard O., Copeland N.G., Jenkins N.A., Sutherland G.R., Baker E., Adams J.M., and Cory S. bcl-w, a novel member of the bcl-2 family, promotes cell survival. Oncogene 13 (1996) 665-675
29. Hua C., Zorn S., Jensen J.P., Coupland R.W., Ko H.S., Wright J.J., and Bakhshi A. Consequences of the t(14;18) chromosomal translocation in follicular lymphoma: deregulated expression of a chimeric and mutated BCL-2 gene. Oncogene Res. 2 (1988) 263-275
30. Saeki K., Yuo A., Okuma E., Yazaki Y., Susin S.A., Kroemer G., and Takaku F. Bcl-2 down-regulation causes autophagy in a caspase-independent manner in human leukemic HL60 cells. Cell Death Differ. 7 (2000) 1263-1269
31. Chan W.-Y., Cheung K.-K., Schorge J.O., Huang L.-W., Welch W.R., Bell D.A., Berkowitz R.S., and Mok S.C. Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am. J. Pathol. 156 (2000) 409-417
32. Liu H.F., Liu W.W., Fang D.C., and Men R.P. Expression of bcl-2 protein in gastric carcinoma and its significance. World J. Gastroenterol. 4 (1998) 228-230
33. Walker C., Robertson L., Myskow M., and Dixon G. Expression of the BCL-2 protein in normal and dysplastic bronchial epithelium and in lung carcinomas. Br. J. Cancer 72 (1995) 164-169
34. Watson A.J. Apoptosis and colorectal cancer. Gut 53 (2004) 1701-1709
35. Sinicrope F.A., Ruan S.B., Cleary K.R., Stephens L.C., Lee J.J., and Levin B. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 55 (1995) 237-241
36. Visca P., Alo P.L., Del Nonno F., Botti C., Trombetta G., Marandino F., Filippi S., Di Tondo U., and Donnorso R.P. Immunohistochemical expression of fatty acid synthase, apoptotic-regulating genes, proliferating factors, and ras protein product in colorectal adenomas, carcinomas, and adjacent nonneoplastic mucosa. Clin. Cancer Res. 5 (1999) 4111-4118
37. An J., Chervin A.S., Nie A., Ducoff H.S., and Huang Z. Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor. Oncogene 26 (2006) 652
38. Violette S., Poulain L., Dussaulx E., Pepin D., Faussat A.M., Chambaz J., Lacorte J.M., Staedel C., and Lesuffleur T. Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int. J. Cancer 98 (2002) 498-504
39. Yang X., Zheng F., Xing H., Gao Q., Wei W., Lu Y., Wang S., Zhou J., Hu W., and Ma D. Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer. J. Cancer Res. Clin. Oncol. 130 (2004) 423-428
40. DiPaola R.S. Approaches to the treatment of patients with hormone-sensitive prostate cancer. Semin. Oncol. 26 (1999) 24-27
41. Baretton G.B., Diebold J., Christoforis G., Vogt M., Muller C., Dopfer K., Schneiderbanger K., Schmidt M., and Lohrs U. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Cancer 77 (1996) 255-264
42. Sinicrope F.A., Hart J., Michelassi F., and Lee J.J. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin. Cancer Res. 1 (1995) 1103-1110
43. Buglioni S., D'Agnano I., Cosimelli M., Vasselli S., D'Angelo C., Tedesco M., Zupi G., and Mottolese M. Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: independent prognostic role of p53 and bcl-2. Int. J. Cancer 84 (1999) 545-552
44. Biden K.G., Simms L.A., Cummings M., Buttenshaw R., Schoch E., Searle J., Gobe G., Jass J.R., Meltzer S.J., Leggett B.A., and Young J. Expression of Bcl-2 protein is decreased in colorectal adenocarcinomas with microsatellite instability. Oncogene 18 (1999) 1245-1249
45. Krajewska M., Kim H., Kim C., Kang H., Welsh K., Matsuzawa S.-i., Tsukamoto M., Thomas R.G., Assa-Munt N., Piao Z., Suzuki K., Perucho M., Krajewski S., and Reed J.C. Analysis of apoptosis protein expression in early-stage colorectal cancer suggests opportunities for new prognostic biomarkers. Clin. Cancer Res. 11 (2005) 5451-5461
46. Manne U., Weiss H.L., and Grizzle W.E. Bcl-2 expression is associated with improved prognosis in patients with distal colorectal adenocarcinomas. Int. J. Cancer 89 (2000) 423-430
47. Meterissian S.H., Kontogiannea M., Al-Sowaidi M., Linjawi A., Halwani F., Jamison B., and Edwardes M. Bcl-2 is a useful prognostic marker in Dukes' B colon cancer. Ann. Surg. Oncol. 8 (2001) 533-537
48. Sinicrope F.A., Hart J., Hsu H.-A., Lemoine M., Michelassi F., and Stephens L.C. Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas. Clin. Cancer Res. 5 (1999) 1793-1804
49. Bosari S., Moneghini L., Graziani D., Lee A.K., Murray J.J., Coggi G., and Viale G. bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. Hum. Pathol. 26 (1995) 534-540
50. Contu P.C., Contu S.S., and Moreira L.F. Bcl-2 expression in rectal cancer. Arq. Gastroenterol. 43 (2006) 284-287
51. Garrity M.M., Burgart L.J., Mahoney M.R., Windschitl H.E., Salim M., Wiesenfeld M., Krook J.E., Michalak J.C., Goldberg R.M., O'Connell M.J., Furth A.F., Sargent D.J., Murphy L.M., Hill E., Riehle D.L., Meyers C.H., and Witzig T.E. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. J. Clin. Oncol. 22 (2004) 1572-1582
52. Bhatavdekar J.M., Patel D.D., Ghosh N., Chikhlikar P.R., Trivedi T.I., Suthar T.P., Doctor S.S., Shah N.G., and Balar D.B. Coexpression of Bcl-2, c-Myc, and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma. Dis. Colon Rectum 40 (1997) 785
53. Bedi A., Pasricha P.J., Akhtar A.J., Barber J.P., Bedi G.C., Giardiello F.M., Zehnbauer B.A., Hamilton S.R., and Jones R.J. Inhibition of apoptosis during development of colorectal cancer. Cancer Res. 55 (1995) 1811-1816
54. Han H.S., Park Y.M., and Hwang T.S. Differential expression of Bcl-2, Bcl-XL and p53 in colorectal cancer. J. Gastroenterol. Hepatol. 21 (2006) 1108-1114
55. van der Woude C.J., Moshage H., Homan M., Kleibeuker J.H., Jansen P.L., and van Dekken H. Expression of apoptosis related proteins during malignant progression in chronic ulcerative colitis. J. Clin. Pathol. 58 (2005) 811-814
56. van der Woude C.J., Jansen P.L., Tiebosch A.T., Beuving A., Homan M., Kleibeuker J.H., and Moshage H. Expression of apoptosis-related proteins in Barrett's metaplasia-dysplasia-carcinoma sequence: a switch to a more resistant phenotype. Hum. Pathol. 33 (2002) 686-692
57. Borner C. Diminished cell proliferation associated with the death-protective activity of Bcl-2. J. Biol. Chem. 271 (1996) 12695-12698
58. Linette G.P., Li Y., Roth K., and Korsmeyer S.J. Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation. Proc. Natl. Acad. Sci. U S A 93 (1996) 9545-9552
59. O'Reilly L.A., Huang D.C., and Strasser A. The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J. 15 (1996) 6979-6990
60. Krajewska M., Moss S.F., Krajewski S., Song K., Holt P.R., and Reed J.C. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res. 56 (1996) 2422-2427
61. Backus H.H., Van Groeningen C.J., Vos W., Dukers D.F., Bloemena E., Wouters D., Pinedo H.M., and Peters G.J. Differential expression of cell cycle and apoptosis related proteins in colorectal mucosa, primary colon tumours, and liver metastases. J. Clin. Pathol. 55 (2002) 206-211
62. Backus H.H., van Riel J.M., van Groeningen C.J., Vos W., Dukers D.F., Bloemena E., Wouters D., Pinedo H.M., and Peters G.J. Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer. Ann. Oncol. 12 (2001) 779-785
63. Wilson J.W., Nostro M.C., Balzi M., Faraoni P., Cianchi F., Becciolini A., and Potten C.S. Bcl-w expression in colorectal adenocarcinoma. Br. J. Cancer 82 (2000) 178-185
64. Wolter K.G., Hsu Y.-T., Smith C.L., Nechushtan A., Xi X.-G., and Youle R.J. Movement of Bax from the cytosol to mitochondria during apoptosis. J. Cell Biol. 139 (1997) 1281-1292
65. Gross A., Jockel J., Wei M.C., and Korsmeyer S.J. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J. 17 (1998) 3878-3885
66. Griffiths G.J., Dubrez L., Morgan C.P., Jones N.A., Whitehouse J., Corfe B.M., Dive C., and Hickman J.A. Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. J. Cell Biol. 144 (1999) 903-914
67. Wei M.C., Zong W.-X., Cheng E.H.Y., Lindsten T., Panoutsakopoulou V., Ross A.J., Roth K.A., MacGregor G.R., Thompson C.B., and Korsmeyer S.J. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292 (2001) 727-730
68. Kandasamy K., Srinivasula S.M., Alnemri E.S., Thompson C.B., Korsmeyer S.J., Bryant J.L., and Srivastava R.K. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release. Cancer Res. 63 (2003) 1712-1721
69. Lindsten T., Ross A.J., King A., Zong W.X., Rathmell J.C., Shiels H.A., Ulrich E., Waymire K.G., Mahar P., Frauwirth K., Chen Y., Wei M., Eng V.M., Adelman D.M., Simon M.C., Ma A., Golden J.A., Evan G., Korsmeyer S.J., MacGregor G.R., and Thompson C.B. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol. Cell 6 (2000) 1389-1399
70. Ogura E., Senzaki H., Yamamoto D., Yoshida R., Takada H., Hioki K., and Tsubura A. Prognostic significance of Bcl-2, Bcl-xL/S, Bax and Bak expressions in colorectal carcinomas. Oncol. Rep. 6 (1999) 365-369
71. Sturm I., Kohne C.H., Wolff G., Petrowsky H., Hillebrand T., Hauptmann S., Lorenz M., Dorken B., and Daniel P.T. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J. Clin. Oncol. 17 (1999) 1364-1374
72. Nehls O., Okech T., Hsieh C.J., Enzinger T., Sarbia M., Borchard F., Gruenagel H.H., Gaco V., Hass H.G., Arkenau H.T., Hartmann J.T., Porschen R., Gregor M., and Klump B. Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX. Br. J. Cancer 96 (2007) 1409-1418
73. Nehls O., Okech T., Hsieh C.J., Sarbia M., Borchard F., Gruenagel H.H., Gaco V., Porschen R., Gregor M., and Klump B. Low BAX protein expression correlates with disease recurrence in preoperatively irradiated rectal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 61 (2005) 85-91
74. Ionov Y., Yamamoto H., Krajewski S., Reed J.C., and Perucho M. Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc. Natl. Acad. Sci. 97 (2000) 10872-10877
75. Miquel C., Borrini F., Grandjouan S., Auperin A., Viguier J., Velasco V., Duvillard P., Praz F., and Sabourin J.C. Role of bax mutations in apoptosis in colorectal cancers with microsatellite instability. Am. J. Clin. Pathol. 123 (2005) 562-570
76. Rampino N., Yamamoto H., Ionov Y., Li Y., Sawai H., Reed J.C., and Perucho M. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275 (1997) 967-969
77. Schwartz Jr. S., Yamamoto H., Navarro M., Maestro M., Reventos J., and Perucho M. Frameshift mutations at mononucleotide repeats in caspase-5 and other target genes in endometrial and gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res. 59 (1999) 2995-3002
78. Trojan J., Brieger A., Raedle J., Weber N., Kriener S., Kronenberger B., Caspary W.F., and Zeuzem S. BAX and caspase-5 frameshift mutations and spontaneous apoptosis in colorectal cancer with microsatellite instability. Int. J. Colorectal Dis. 19 (2004) 538-544
79. Abdel-Rahman W.M., Georgiades I.B., Curtis L.J., Arends M.J., and Wyllie A.H. Role of BAX mutations in mismatch repair-deficient colorectal carcinogenesis. Oncogene 18 (1999) 2139-2142
80. Sakamoto I., Yamada T., Ohwada S., Koyama T., Nakano T., Okabe T., Hamada K., Kawate S., Takeyoshi I., Iino Y., and Morishita Y. Mutational analysis of the BAK gene in 192 advanced gastric and colorectal cancers. Int. J. Mol. Med. 13 (2004) 53-55
81. Yang E., Zha J., Jockel J., Boise L.H., Thompson C.B., and Korsmeyer S.J. Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces bax and promotes cell death. Cell 80 (1995) 285-291
82. Zha J., Harada H., Yang E., Jockel J., and Korsmeyer S.J. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-XL. Cell 87 (1996) 619-628
83. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., and Greenberg M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 (1997) 231-241
84. Lee J.W., Soung Y.H., Kim S.Y., Nam S.W., Kim C.J., Cho Y.G., Lee J.H., Kim H.S., Park W.S., Kim S.H., Lee J.Y., Yoo N.J., and Lee S.H. Inactivating mutations of proapoptotic Bad gene in human colon cancers. Carcinogenesis 25 (2004) 1371-1376
85. Khor T.O., Gul Y.A., Ithnin H., and Seow H.F. Positive correlation between overexpression of phospho-BAD with phosphorylated Akt at serine 473 but not threonine 308 in colorectal carcinoma. Cancer Lett. 210 (2004) 139-150
86. Kim M.R., Jeong E.G., Chae B., Lee J.W., Soung Y.H., Nam S.W., Lee J.Y., Yoo N.J., and Lee S.H. Pro-apoptotic PUMA and anti-apoptotic phospho-BAD are highly expressed in colorectal carcinomas. Dig. Dis. Sci. 52 (2007) 2751-2756
87. Sinicrope F.A., Rego R.L., Foster N.R., Thibodeau S.N., Alberts S.R., Windschitl H.E., and Sargent D.J. Proapoptotic Bad and Bid protein expression predict survival in stages II and III colon cancers. Clin. Cancer Res. 14 (2008) 4128-4133
88. Nakano K., and Vousden K.H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 7 (2001) 683-694
89. Han J., Flemington C., Houghton A.B., Gu Z., Zambetti G.P., Lutz R.J., Zhu L., and Chittenden T. Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals. Proc. Natl. Acad. Sci. U S A 98 (2001) 11318-11323
90. Oda E., Ohki R., Murasawa H., Nemoto J., Shibue T., Yamashita T., Tokino T., Taniguchi T., and Tanaka N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288 (2000) 1053-1058
91. Diallo J.S., Aldejmah A., Mouhim A.F., Peant B., Fahmy M.A., Koumakpayi I.H., Sircar K., Begin L.R., Mes-Masson A.M., and Saad F. NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model. Clin. Cancer Res. 13 (2007) 7044-7052
92. Jansson A., Arbman G., and Sun X.F. mRNA and protein expression of PUMA in sporadic colorectal cancer. Oncol. Rep. 12 (2004) 1245-1249
93. Jansson A.K., Emterling A.M., Arbman G., and Sun X.F. Noxa in colorectal cancer: a study on DNA, mRNA and protein expression. Oncogene 22 (2003) 4675-4678
94. Abdel-Rahman W.M., Arends M.J., Morris R.G., Ramadan M.E., and Wyllie A.H. Death pathway genes Fas (Apo-1/CD95) and Bik (Nbk) show no mutations in colorectal carcinomas. Cell Death Differ. 6 (1999) 387-388
95. Li P., Nijhawan D., Budihardjo I., Srinivasula S.M., Ahmad M., Alnemri E.S., and Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91 (1997) 479-489
96. Zou H., Li Y., Liu X., and Wang X. An APAF-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J. Biol. Chem. 274 (1999) 11549-11556
97. Barczyk K., Kreuter M., Pryjma J., Booy E.P., Maddika S., Ghavami S., Berdel W.E., Roth J., and Los M. Serum cytochrome c indicates in vivo apoptosis and can serve as a prognostic marker during cancer therapy. Int. J. Cancer 116 (2005) 167-173
98. Zlobec I., Vuong T., and Compton C.C. The predictive value of apoptosis protease-activating factor 1 in rectal tumors treated with preoperative, high-dose-rate brachytherapy. Cancer 106 (2006) 284-286
99. Zlobec I., Lugli A., Baker K., Roth S., Minoo P., Hayashi S., Terracciano L., and Jass J.R. Role of APAF-1, E-cadherin and peritumoral lymphocytic infiltration in tumour budding in colorectal cancer. J. Pathol. 212 (2007) 260-268
100. Soengas M.S., Capodieci P., Polsky D., Mora J., Esteller M., Opitz-Araya X., McCombie R., Herman J.G., Gerald W.L., Lazebnik Y.A., Cordon-Cardo C., and Lowe S.W. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409 (2001) 207-211
101. Lakhani S.A., Masud A., Kuida K., Porter Jr. G.A., Booth C.J., Mehal W.Z., Inayat I., and Flavell R.A. Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science 311 (2006) 847-851
102. Palmerini F., Devilard E., Jarry A., Birg F., and Xerri L. Caspase 7 downregulation as an immunohistochemical marker of colonic carcinoma. Hum. Pathol. 32 (2001) 461-467
103. Soung Y.H., Lee J.W., Kim S.Y., Park W.S., Nam S.W., Lee J.Y., Yoo N.J., and Lee S.H. Somatic mutations of CASP3 gene in human cancers. Hum. Genet. 115 (2004) 112-115
104. Soung Y.H., Lee J.W., Kim H.S., Park W.S., Kim S.Y., Lee J.H., Park J.Y., Cho Y.G., Kim C.J., Park Y.G., Nam S.W., Jeong S.W., Kim S.H., Lee J.Y., Yoo N.J., and Lee S.H. Inactivating mutations of CASPASE-7 gene in human cancers. Oncogene 22 (2003) 8048-8052
105. Putt K.S., Chen G.W., Pearson J.M., Sandhorst J.S., Hoagland M.S., Kwon J.T., Hwang S.K., Jin H., Churchwell M.I., Cho M.H., Doerge D.R., Helferich W.G., and Hergenrother P.J. Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nat. Chem. Biol. 2 (2006) 543-550
106. Leonardos L., Butler L.M., Hewett P.J., Zalewski P.D., and Cowled P.A. The activity of caspase-3-like proteases is elevated during the development of colorectal carcinoma. Cancer Lett. 143 (1999) 29-35
107. Roy N., Deveraux Q.L., Takahashi R., Salvesen G.S., and Reed J.C. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J. 16 (1997) 6914-6925
108. Deveraux Q.L., Takahashi R., Salvesen G.S., and Reed J.C. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388 (1997) 300-304
109. Ambrosini G., Adida C., and Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3 (1997) 917-921
110. Schimmer A.D. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res. 64 (2004) 7183-7190
111. Hoffmann A.C., Warnecke-Eberz U., Luebke T., Prenzel K., Metzger R., Heitmann M., Neiss S., Vallbohmer D., Hoelscher A.H., and Schneider P.M. Survivin mRNA in peripheral blood is frequently detected and significantly decreased following resection of gastrointestinal cancers. J. Surg. Oncol. 95 (2007) 51-54
112. Ponnelle T., Chapusot C., Martin L., Bouvier A.M., Plenchette S., Faivre J., Solary E., and Piard F. Cellular localisation of survivin: impact on the prognosis in colorectal cancer. J. Cancer Res. Clin. Oncol. 131 (2005) 504-510
113. Sarela A.I., Scott N., Ramsdale J., Markham A.F., and Guillou P.J. Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage II colorectal carcinomas. Ann. Surg. Oncol. 8 (2001) 305-310
114. Altieri D.C. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr. Opin. Cell Biol. 18 (2006) 609-615
115. Dohi T., Beltrami E., Wall N.R., Plescia J., and Altieri D.C. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J. Clin. Invest. 114 (2004) 1117-1127
116. Sarela A.I., Macadam R.C., Farmery S.M., Markham A.F., and Guillou P.J. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 46 (2000) 645-650
117. Kawasaki H., Altieri D.C., Lu C.D., Toyoda M., Tenjo T., and Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 58 (1998) 5071-5074
118. Rohayem J., Diestelkoetter P., Weigle B., Oehmichen A., Schmitz M., Mehlhorn J., Conrad K., and Rieber E.P. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res. 60 (2000) 1815-1817
119. Krajewska M., Krajewski S., Banares S., Huang X., Turner B., Bubendorf L., Kallioniemi O.-P., Shabaik A., Vitiello A., Peehl D., Gao G.-J., and Reed J.C. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin. Cancer Res. 9 (2003) 4914-4925
120. Yoo N.J., Kim H.S., Kim S.Y., Park W.S., Park C.H., Jeon H.M., Jung E.S., Lee J.Y., and Lee S.H. Immunohistochemical analysis of Smac/DIABLO expression in human carcinomas and sarcomas. APMIS 111 (2003) 382-388
121. Ma T.L., Ni P.H., Zhong J., Tan J.H., Qiao M.M., and Jiang S.H. Low expression of XIAP-associated factor 1 in human colorectal cancers. Chin. J. Dig. Dis. 6 (2005) 10-14
122. O'Connell J., O'Sullivan G.C., Collins J.K., and Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184 (1996) 1075-1082
123. O'Connell J., Houston A., Bennett M.W., O'Sullivan G.C., and Shanahan F. Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat. Med. 7 (2001) 271-274
124. Restifo N.P. Countering the 'counterattack' hypothesis. Nat. Med. 7 (2001) 259
125. Michael-Robinson J.M., Pandeya N., Cummings M.C., Walsh M.D., Young J.P., Leggett B.A., Purdie D.M., Jass J.R., and Radford-Smith G.L. Fas ligand and tumour counter-attack in colorectal cancer stratified according to microsatellite instability status. J. Pathol. 201 (2003) 46-54
126. Houston A.M., Michael-Robinson J.M., Walsh M.D., Cummings M.C., Ryan A.E., Lincoln D., Pandeya N., Jass J.R., Radford-Smith G.L., and O'Connell J. The "Fas counterattack" is not an active mode of tumor immune evasion in colorectal cancer with high-level microsatellite instability. Hum. Pathol. 39 (2008) 243-250
127. Belluco C., Esposito G., Bertorelle R., Alaggio R., Giacomelli L., Bianchi L.C., Nitti D., and Lise M. Fas ligand is up-regulated during the colorectal adenoma-carcinoma sequence. Eur. J. Surg. Oncol. 28 (2002) 120-125
128. Nozoe T., Yasuda M., Honda M., Inutsuka S., and Korenaga D. Fas ligand expression is correlated with metastasis in colorectal carcinoma. Oncology 65 (2003) 83-88
129. Sheehan K.M., O'Donovan D.G., Fitzmaurice G., O'Grady A., O'Donoghue D.P., Sheahan K., Byrne M.F., Conroy R.M., Kay E.W., and Murray F.E. Prognostic relevance of Fas (APO-1/CD95) ligand in human colorectal cancer. Eur. J. Gastroenterol. Hepatol. 15 (2003) 375-380
130. Tillman D.M., Petak I., and Houghton J.A. A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells. Clin. Cancer Res. 5 (1999) 425-430
131. Bezulier K., Fina F., Roussel M., Bun S.S., Ciccolini J., Martin P.M., Milano G., Aubert C., and Barra Y. Fas/FasL expression in tumor biopsies: a prognostic response factor to fluoropyrimidines?. J. Clin. Pharm. Ther. 28 (2003) 403-408
132. Kushlinskii N.E., Britvin T.A., Abbasova S.G., Perevoshchikov A.G., Prorokov V.V., Kostanyan I.A., Knysh V.I., and Lipkin V.M. Soluble Fas antigen in the serum of patients with colon cancer. Bull. Exp. Biol. Med. 131 (2001) 361-363
133. Nadal C., Maurel J., Gallego R., Castells A., Longaron R., Marmol M., Sanz S., Molina R., Martin-Richard M., and Gascon P. FAS/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer. Clin. Cancer Res. 11 (2005) 4770-4774
134. Griffith T.S., Chin W.A., Jackson G.C., Lynch D.H., and Kubin M.Z. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. 161 (1998) 2833-2840
135. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., Sutherland G.R., Smith T.D., Rauch C., Smith C.A., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 (1995) 673-682
136. A. Ashkenazi, Targeting the extrinsic apoptosis pathway in cancer, Cytokine and growth factor reviews In press, Corrected proof.
137. Koornstra J.J., Kleibeuker J.H., van Geelen C.M., Rijcken F.E., Hollema H., de Vries E.G., and de Jong S. Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J. Pathol. 200 (2003) 327-335
138. Strater J., Hinz U., Walczak H., Mechtersheimer G., Koretz K., Herfarth C., Moller P., and Lehnert T. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin. Cancer Res. 8 (2002) 3734-3740
139. van Geelen C.M., Westra J.L., de Vries E.G., Boersma-van Ek W., Zwart N., Hollema H., Boezen H.M., Mulder N.H., Plukker J.T., de Jong S., Kleibeuker J.H., and Koornstra J.J. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J. Clin. Oncol. 24 (2006) 4998-5004
140. Pitti R.M., Marsters S.A., Lawrence D.A., Roy M., Kischkel F.C., Dowd P., Huang A., Donahue C.J., Sherwood S.W., Baldwin D.T., Godowski P.J., Wood W.I., Gurney A.L., Hillan K.J., Cohen R.L., Goddard A.D., Botstein D., and Ashkenazi A. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396 (1998) 699-703
141. Yu K.-Y., Kwon B., Ni J., Zhai Y., Ebner R., and Kwon B.S. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J. Biol. Chem. 274 (1999) 13733-13736
142. Mild G., Bachmann F., Boulay J.L., Glatz K., Laffer U., Lowy A., Metzger U., Reuter J., Terracciano L., Herrmann R., and Rochlitz C. DCR3 locus is a predictive marker for 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer. Int. J. Cancer 102 (2002) 254-257
143. Kim H.S., Lee J.W., Soung Y.H., Park W.S., Kim S.Y., Lee J.H., Park J.Y., Cho Y.G., Kim C.J., Jeong S.W., Nam S.W., Kim S.H., Lee J.Y., Yoo N.J., and Lee S.H. Inactivating mutations of caspase-8 gene in colorectal carcinomas. Gastroenterology 125 (2003) 708-715
144. Kim K., Fisher M.J., Xu S.-Q., and El-Deiry W.S. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin. Cancer Res. 6 (2000) 335-346
145. Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., Bodmer J.-L., Schroter M., Burns K., Mattmann C., Rimoldi D., French L.E., and Tschopp J. Inhibition of death receptor signals by cellular FLIP. Nature 388 (1997) 190-195
146. Ryu B.K., Lee M.G., Chi S.G., Kim Y.W., and Park J.H. Increased expression of cFLIP(L) in colonic adenocarcinoma. J. Pathol. 194 (2001) 15-19
147. Ullenhag G.J., Mukherjee A., Watson N.F.S., Al-Attar A.H., Scholefield J.H., and Durrant L.G. Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clin. Cancer Res. 13 (2007) 5070-5075
148. Wang K., Yin X.M., Chao D.T., Milliman C.L., and Korsmeyer S.J. BID: a novel BH3 domain-only death agonist. Genes Dev. 10 (1996) 2859-2869
149. Luo X., Budihardjo I., Zou H., Slaughter C., and Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94 (1998) 481-490
150. Li H., Zhu H., Xu C.J., and Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94 (1998) 491-501
151. Krajewska M., Zapata J.M., Meinhold-Heerlein I., Hedayat H., Monks A., Bettendorf H., Shabaik A., Bubendorf L., Kallioniemi O.P., Kim H., Reifenberger G., Reed J.C., and Krajewski S. Expression of Bcl-2 family member Bid in normal and malignant tissues. Neoplasia 4 (2002) 129-140
152. Cande C., Vahsen N., Garrido C., and Kroemer G. Apoptosis-inducing factor (AIF): caspase-independent after all. Cell Death Differ. 11 (2004) 591-595
153. Susin S.A., Lorenzo H.K., Zamzami N., Marzo I., Snow B.E., Brothers G.M., Mangion J., Jacotot E., Costantini P., Loeffler M., Larochette N., Goodlett D.R., Aebersold R., Siderovski D.P., Penninger J.M., and Kroemer G. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397 (1999) 441-446
154. Urbano A., Lakshmanan U., Choo P.H., Kwan J.C., Ng P.Y., Guo K., Dhakshinamoorthy S., and Porter A. AIF suppresses chemical stress-induced apoptosis and maintains the transformed state of tumor cells. EMBO J. 24 (2005) 2815-2826
155. Jeong E.G., Lee J.W., Soung Y.H., Nam S.W., Kim S.H., Lee J.Y., Yoo N.J., and Lee S.H. Immunohistochemical and mutational analysis of apoptosis-inducing factor (AIF) in colorectal carcinomas. APMIS 114 (2006) 867-873
156. Klionsky D.J., and Emr S.D. Autophagy as a regulated pathway of cellular degradation. Science 290 (2000) 1717-1721
157. Kondo Y., Kanzawa T., Sawaya R., and Kondo S. The role of autophagy in cancer development and response to therapy. Nat. Rev. Cancer 5 (2005) 726-734
158. Shintani T., and Klionsky D.J. Autophagy in health and disease: a double-edged sword. Science 306 (2004) 990-995
159. Yue Z., Jin S., Yang C., Levine A.J., and Heintz N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc. Natl. Acad. Sci. U S A 100 (2003) 15077-15082
160. Ahn C.H., Jeong E.G., Lee J.W., Kim M.S., Kim S.H., Kim S.S., Yoo N.J., and Lee S.H. Expression of beclin-1, an autophagy-related protein, in gastric and colorectal cancers. APMIS 115 (2007) 1344-1349
161. Lee J.W., Jeong E.G., Lee S.H., Yoo N.J., and Lee S.H. Somatic mutations of BECN1, an autophagy-related gene, in human cancers. APMIS 115 (2007) 750-756
162. Schwandner O., Schiedeck T.H., Bruch H.P., Duchrow M., Windhoevel U., and Broll R. p53 and Bcl-2 as significant predictors of recurrence and survival in rectal cancer. Eur. J. Cancer 36 (2000) 348-356
163. Hilska M., Collan Y.U., VJ O.L., Kossi J., Hirsimaki P., Laato M., and Roberts P.J. The significance of tumor markers for proliferation and apoptosis in predicting survival in colorectal cancer. Dis. Colon Rectum 48 (2005) 2197-2208
164. Tornillo L., Lugli A., Zlobec I., Willi N., Glatz K., Lehmann F., Spichtin H.P., Maurer R., Stoios D., Sauter G., and Terracciano L. Prognostic value of cell cycle and apoptosis regulatory proteins in mismatch repair-proficient colorectal cancer: a tissue microarray-based approach. Am. J. Clin. Pathol. 127 (2007) 114-123
165. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ. 10 (2003) 431-442
166. Yu J., Wang Z., Kinzler K.W., Vogelstein B., and Zhang L. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc. Natl. Acad. Sci. U S A 100 (2003) 1931-1936
167. Haupt S., Berger M., Goldberg Z., and Haupt Y. Apoptosis - the p53 network. J. Cell Sci. 116 (2003) 4077-4085
168. Graziano F., and Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough?. Ann. Oncol. 14 (2003) 1026-1038
169. Buglioni S., D'Agnano I., Vasselli S., Perrone Donnorso R., D'Angelo C., Brenna A., Benevolo M., Cosimelli M., Zupi G., and Mottolese M. p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant therapy. Am. J. Clin. Pathol. 116 (2001) 360-368
170. Paradiso A., Simone G., Lena M.D., Leone B., Vallejo C., Lacava J., Dellapasqua S., Daidone M.G., and Costa A. Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer. Br. J. Cancer 84 (2001) 651-658
171. Letai A.G. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat. Rev. Cancer 8 (2008) 121-132
172. Huber H.J., Rehm M., Plchut M., Dussmann H., and Prehn J.H. APOPTO-CELL-a simulation tool and interactive database for analyzing cellular susceptibility to apoptosis. Bioinformatics 23 (2007) 648-650
173. Rehm M., Huber H.J., Dussmann H., and Prehn J.H. Systems analysis of effector caspase activation and its control by X-linked inhibitor of apoptosis protein. EMBO J. 25 (2006) 4338-4349
174. Albeck J.G., Burke J.M., Aldridge B.B., Zhang M., Lauffenburger D.A., and Sorger P.K. Quantitative analysis of pathways controlling extrinsic apoptosis in single cells. Mol. Cell 30 (2008) 11-25
175. Wilson T.R., Longley D.B., and Johnston P.G. Chemoresistance in solid tumours. Ann. Oncol. 17 (2006) x315-x324
176. O'Brien C.A., Pollett A., Gallinger S., and Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445 (2007) 106-110
177. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., and De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature 445 (2007) 111-115
178. Dalerba P., Dylla S.J., Park I.K., Liu R., Wang X., Cho R.W., Hoey T., Gurney A., Huang E.H., Simeone D.M., Shelton A.A., Parmiani G., Castelli C., and Clarke M.F. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. U S A 104 (2007) 10158-10163
179. Dean M., Fojo T., and Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 5 (2005) 275-284
180. Ricci-Vitiani L., Pagliuca A., Palio E., Zeuner A., and De Maria R. Colon cancer stem cells. Gut 57 (2008) 538-548
181. Shmelkov S.V., Butler J.M., Hooper A.T., Hormigo A., Kushner J., Milde T., St Clair R., Baljevic M., White I., Jin D.K., Chadburn A., Murphy A.J., Valenzuela D.M., Gale N.W., Thurston G., Yancopoulos G.D., D'Angelica M., Kemeny N., Lyden D., and Rafii S. CD133 expression is not restricted to stem cells, and both CD133+ and CD133-metastatic colon cancer cells initiate tumors. J. Clin. Invest. 118 (2008) 2111-2120
182. Silke L., and Oliver G.O. The new look of colorectal cancer stem cells. Gastroenterology 134 (2008) 1262-1264